Last reviewed 2026-05-30 · How we verify

Medium Dose PF-07328948 (medium-dose-pf-07328948)

Medium Dose PF-07328948 (generic name: medium-dose-pf-07328948) is a Unknown drug developed by Pfizer. It is currently FDA-approved for COVID-19.

Medium Dose PF-07328948 is being studied in a clinical trial for the treatment of heart failure. The trial, titled "A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)," is a phase 2, randomized, double-blind, placebo-controlled study.

At a glance

Approved indications

• COVID-19

Common side effects

No common side effects on file.

Drug interactions

• Atazanavir
• Cobicistat
• Darunavir
• Lopinavir
• Ritonavir
• Saquinavir
• Tipranavir
• Fosamprenavir
• Indinavir
• Etravirine
• Nelfinavir
• Rilpivirine

Key clinical trials

• A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Medium Dose PF-07328948 CI brief — competitive landscape report
• Medium Dose PF-07328948 updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Medium Dose PF-07328948

Related

• Drug class: All Unknown drugs
• Target: All drugs targeting Unknown
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for COVID-19

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing